Compounds that inhibit mcl-1 protein
US-2020062780-A1 · Feb 27, 2020 · US
Compounds that inhibit MCL-1 protein
US12024529B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12024529-B2 |
| Application number | US-202318313703-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 8, 2023 |
| Priority date | Aug 29, 2014 |
| Publication date | Jul 2, 2024 |
| Grant date | Jul 2, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound, wherein the compound has the following formula:
Assignees
Inventors
Classifications
Benzotriazoles · CPC title
of an acyclic unsaturated carbon skeleton · CPC title
containing halogen · CPC title
the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring · CPC title
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (4-oxa-1-azabicyclo [3.2.0] heptanes, e.g. oxapenicillins C07D503/00; 5-oxa-1-azabicyclo [4.2.0] octanes, e.g. oxacephalosporins C07D505/00; analogues thereof having ring oxygen atoms in other position C07D507/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12024529B2 cover?
- Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,and pharmaceutically acceptable salts thereof and pharmaceutical co…
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).